NTZ

Natuzzi S.p.A. Announces Dates for the Fourth Quarter and Full Year 2023 Financial Information and Conference Call

Retrieved on: 
Wednesday, April 3, 2024
Retail, Luxury, Other Retail, Home Goods, Manufacturing, Other Manufacturing, Person, NTZ

Natuzzi S.p.A. (NYSE: NTZ) (“Natuzzi” or the “Company”) will disclose its unaudited 2023 fourth quarter and full year financial information on Friday April 5, 2024, after the market closes.

Key Points: 
  • Natuzzi S.p.A. (NYSE: NTZ) (“Natuzzi” or the “Company”) will disclose its unaudited 2023 fourth quarter and full year financial information on Friday April 5, 2024, after the market closes.
  • The Company will host a conference call on Monday April 8, 2024, at 10:00 a.m. U.S. Eastern time (4.00 p.m. Italy time, or 3.00 p.m. UK time) to discuss financial information.
  • To join live the conference call, interested persons will need to either:
    i) dial-in the following number:
    ii) click on the following link:
    https://www.c-meeting.com/web3/join/3PQUFXRW48XTKQ to join via video.
  • To access the replay of the conference call, interested persons need to dial + 1-844-512-2921 (toll-free) for calls from U.S. and Canada, or + 1-412-317-6671 for calls from other countries.

GENFIT Announces Revenues and Cash Position as of December 31, 2023

Retrieved on: 
Thursday, February 29, 2024
Marketing, EMA, New Drug Application, MAA, Annual report, FDA, Food, Part, PDUFA, NTZ, PBC, Primary biliary cholangitis, Collaboration, European Medicines Agency, Patient, Elafibranor, NDA, Research, Priority review, Pharmaceutical industry

As of December 31, 2023, the Company’s cash and cash equivalents amounted to €77.8 million compared with €140.2 million as of December 31, 2022.

Key Points: 
  • As of December 31, 2023, the Company’s cash and cash equivalents amounted to €77.8 million compared with €140.2 million as of December 31, 2022.
  • As of September 30, 2023, cash and cash equivalents totaled €93.9 million.
  • Revenues for 2023 amounted to €28.6 million compared to €20.2 million for the same period in 2022.
  • The 2023 Universal Registration Document, the 2023 Annual Financial Report (included in the 2023 Universal Registration Document), and the Annual Report on Form 20-F will be published by the end of April 2024.

GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)

Retrieved on: 
Friday, December 8, 2023
Hepatic encephalopathy, Ipsen, AASLD, Cell death, Food, Itch, Priority review, Food and Drug Administration, PSC, IND, ACLF, Marketing, FDA, EMA, MAA, PDUFA, Permeability (electromagnetism), Liver, NDA, Inflammation, Primary sclerosing cholangitis, ALP, Capital market, Hyperammonemia, Patient, NTZ, Fibrosis, PBC, ASK1

Launches in the US and Europe will also make GENFIT eligible for royalty payments.

Key Points: 
  • Launches in the US and Europe will also make GENFIT eligible for royalty payments.
  • Revenues will fund the development of GENFIT’s pipeline, now mainly focused on Acute On-Chronic Liver Failure (ACLF) with 5 differentiated assets.
  • Acceptance of filings in the US and Europe have triggered the first milestone payment for GENFIT.
  • Ipsen also indicated that it is developing elafibranor in Primary Sclerosing Cholangitis (PSC) which could lead to further revenues for GENFIT under the licensing agreement.

Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

Retrieved on: 
Thursday, December 7, 2023
Liver, UDCA, Chapter Two, Woman, FDA, MAA, Fatigue, Nausea, Primary biliary cholangitis, Inflammation, ADR, Patent, Liver disease, Diagnosis, AMF, CHMP, Ascending cholangitis, UCD, Business, ACLF, PDUFA, Itch, Risk, New Drug Application, OA, Common, EASL, MASH, Liver failure, Safety, Ammonia, Elafibranor, Therapy, Epidemiology, History, Patient, Cholangiocarcinoma, Food, Health care, EMA, Ursodeoxycholic acid, MHRA, Cirrhosis, Medicine, NTZ, EVP, Cholestasis, NASH, Research, Diarrhea, Bile, NDA, PBC, Abdominal pain, Clinical trial, European Medicines Agency, IPN, PPAR, P10, CCA, Fibrosis, Pharmaceutical industry

An oral, once-daily dual peroxisome activated receptor alpha/delta (PPAR α,δ) agonist, investigational elafibranor could potentially be the first novel second-line treatment for the rare, cholestatic liver disease, PBC, in nearly a decade.

Key Points: 
  • An oral, once-daily dual peroxisome activated receptor alpha/delta (PPAR α,δ) agonist, investigational elafibranor could potentially be the first novel second-line treatment for the rare, cholestatic liver disease, PBC, in nearly a decade.
  • The trial enrolled 161 patients who were randomized 2:1 to receive either elafibranor 80mg once daily or placebo.
  • ELATIVE also investigated the effect of treatment with elafibranor on pruritus (severe itch), a significant symptom burden amongst people living with PBC.
  • Findings from the secondary endpoint using the PBC Worst Itch NRS score, showed a reduction in pruritis for elafibranor, which was not statistically significant.

GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023

Retrieved on: 
Thursday, November 16, 2023
Multiple organ dysfunction syndrome, Primary biliary cholangitis, Permeability (electromagnetism), Hepatic encephalopathy, PBC, AASLD, IND, Disease, Mortality, Cirrhosis, Elafibranor, UCSF, Patient, Heart, Liver, ASK1, Caregiver, NTZ, Chronic liver disease, Cell death, MBA, MD, University, Transplant, Doctor of Philosophy, Microbiota, Fibrosis, Ipsen, University of California, European Foundation, Human, Inflammation, Pharmaceutical industry, ACLF, Hyperammonemia, Boston, Euronext

GENFIT is now mainly focused on the development of therapies for ACLF which is an area of very high unmet medical need.

Key Points: 
  • GENFIT is now mainly focused on the development of therapies for ACLF which is an area of very high unmet medical need.
  • ACLF is a potentially deadly, but reversible, condition in patients with chronic liver diseases, which is associated with multi-organ failure and high short-term mortality.
  • Pascal Prigent, CEO of GENFIT, commented: “During AASLD we were excited to further discuss our development strategy around our new pipeline focused on ACLF, where we believe multiple programs have the potential to transform the treatment paradigm for these patients.
  • As part of the “ACLF Day” event during AASLD, the critical need for treatment has been highlighted by leading experts in ACLF.

GENFIT Reports Third Quarter 2023 Financial Information

Retrieved on: 
Thursday, November 9, 2023
Research, ACLF, PBC, Patient, Part, Collaboration, NTZ, Primary biliary cholangitis, Cryptocurrency, Pharmaceutical industry, Euronext, Ipsen

As of September 30, 2023, the Company’s cash and cash equivalents amounted to €93.9 million compared with €163.6 million a year earlier.

Key Points: 
  • As of September 30, 2023, the Company’s cash and cash equivalents amounted to €93.9 million compared with €163.6 million a year earlier.
  • As of June 30, 2023, cash and cash equivalents totaled €111.8 million.
  • We expect that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements until approximately the fourth quarter of 2024.
  • Revenue2 for the first nine months of 2023 amounted to €14.3 million compared to €14.1 million for the same period in 2022.

Natuzzi S.P.A. Announces Dates for the Third Quarter 2023 Financial Information and Conference Call

Retrieved on: 
Wednesday, November 15, 2023
Retail, Luxury, Other Retail, Home Goods, Manufacturing, Other Manufacturing, NTZ, NYSE, Person

Natuzzi S.p.A. (NYSE: NTZ) (“Natuzzi” or the “Company”) will disclose its unaudited 2023 third quarter financial information on Friday November 24, 2023, after the market closes.

Key Points: 
  • Natuzzi S.p.A. (NYSE: NTZ) (“Natuzzi” or the “Company”) will disclose its unaudited 2023 third quarter financial information on Friday November 24, 2023, after the market closes.
  • The Company will host a conference call on Monday November 27, 2023, at 10:00 a.m. U.S. Eastern time (4.00 p.m. Italy time, or 3.00 p.m. UK time) to discuss financial information.
  • To join the live conference call, interested persons will need to either:
    i) dial-in the following number:
    ii) click on the following link:
    https://www.c-meeting.com/web3/join/3PQUFXRW48XTKQ to join via video.
  • A replay of the call will be available from Monday November 27, 2023, approximately 3 hours after conference end time, until Wednesday, December 27, 2023, at 11:59 pm U.S.

Natuzzi S.p.A. Announces Dates For the Second Quarter 2023 Financial Information and Conference Call

Retrieved on: 
Friday, September 15, 2023
Manufacturing, Home Goods, Other Manufacturing, Luxury, Retail, NTZ, NYSE, Person

Natuzzi S.p.A. (NYSE: NTZ) (“Natuzzi” or the “Company”) will disclose its unaudited 2023 second quarter financial information on Friday September 29, 2023, after the market closes.

Key Points: 
  • Natuzzi S.p.A. (NYSE: NTZ) (“Natuzzi” or the “Company”) will disclose its unaudited 2023 second quarter financial information on Friday September 29, 2023, after the market closes.
  • The Company will host a conference call on Monday October 2, 2023, at 10:00 a.m. U.S. Eastern time (4.00 p.m. Italy time, or 3.00 p.m. UK time) to discuss financial information.
  • To join the live conference call, interested persons will need to either:
    click on the following link:
    https://www.c-meeting.com/web3/join/3PQUFXRW48XTKQ to join via video.
  • A replay of the call will be available from Monday October 2, 2023, approximately 3 hours after conference end time, until Thursday, November 02, 2023 at 11:59 PM ET.

GENFIT Announces New Data at the European Association for the Study of the Liver (EASL) Congress 2023

Retrieved on: 
Wednesday, June 7, 2023
Abstract, EASL, Diagnosis, NASH, Hepatology, NIT, NTZ, Congress, Patient, NAFLD, Medical device, ACLF, Euronext

Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); June 7, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it will present new data at the EASL Congress which will take place on June 21-24, 2023 in Vienna, Austria.

Key Points: 
  • Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); June 7, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it will present new data at the EASL Congress which will take place on June 21-24, 2023 in Vienna, Austria.
  • GENFIT has had three abstracts accepted for poster sessions.
  • Session: June 24, 2023 between 9.00am – 5.00pm at NAFLD: Diagnostics and non-invasive assessment (selected for inclusion in the Best of EASL Congress summary slide deck).
  • Session: June 24, 2023 between 9.00am – 5.00pm at NAFLD: Diagnostics and non-invasive assessment
    GENFIT will host an investigator meeting on June 22, 2023 in relation to the international UNVEIL-IT™ Phase 2 study which is currently being conducted, evaluating VS-01 in ACLF.

Natuzzi S.p.A: First Quarter 2023 Financial Results and Shareholder Letter

Retrieved on: 
Friday, June 2, 2023
Manufacturing, Home Goods, Other Manufacturing, Luxury, Retail, Communication, Partnership, Housing, Natuzzi, SG, Face, DOS, NTZ, Economics, Attitude, Sale, Plant, Investment, Freezing, Collection, Outsourcing, Growth, NYSE, Video game, Sales, Interior design

The overstock is gradually easing but is not solved yet and still represents a burden for the introduction of new collections.

Key Points: 
  • The overstock is gradually easing but is not solved yet and still represents a burden for the introduction of new collections.
  • Natuzzi Editions products are distributed in Italy under the brand Divani&Divani by Natuzzi.
  • Invoiced sales from our unbranded business amounted to €6.5 million in 1Q 2023, from €15.0 million and from €23.6 million in 2022 and 2019 first quarter, respectively.
  • Here below a breakdown of 1Q 2023 upholstery and home-furnishings invoiced sales compared to 1Q 2022, according to the following geographic areas.